Current/ Expected Orderbook/ Pending Orders?

Total order intake in the reported quarter was ₹10.63 billion, with 68% from bioenergy. CPES business's ETCA segment holds a significant 52% share in the overall order book. PHS business crossed ₹100 crore in order booking for the quarter. CBG segment has one confirmed order of around ₹100 crore; ₹400 crore worth orders are still at L1 stage as of 1st November. Five CBG projects awarded, with some delays due to land and registration issues, expected to progress once resolved. Healthy pipeline for 1G starch-based ethanol projects, with some temporary slowdown due to feedstock policies. Export o

Any current/future new fundraising through debt or equity?

The transcript on page 18 and surrounding pages does not mention any current or planned fundraising through debt or equity. There is no discussion or indication of new capital raising activities. The focus is mainly on capital expenditure (CAPEX) plans (e.g., Rs. 100 crore for Genx facility, Rs. 40 crore for pilot plants), but funding sources for these are not explicitly stated as new debt or equity. Cash balance reported as Rs. 6.87 billion (Rs. 687 crore) as of Sept 30, 2023, which suggests internal resources may be used. No explicit mention of issuing new shares or taking on new loan facili

Any current/future capex/capital investment/strategic investment?

Praj Industries is setting up a new Genx manufacturing facility at Mangalore with commercial production expected by Feb-Mar FY24 end. Total CAPEX related to Genx is estimated at ₹100 crore, with ₹60 crore planned for the current year and ₹40 crore for the next year. Additional routine CAPEX for other facilities and IT is planned in the range of ₹15-20 crore. Two pilot plants are being set up for SAF (Sustainable Aviation Fuel) and PLA (Polylactic Acid) with a CAPEX of around ₹40 crore this year. Total CAPEX for the current year including Genx, routine expenses, and pilot plants is approximatel

Future growth expectations in earnings/operating earnings/profits/EPS?

Positive business outlook with momentum building in international markets, especially in bioenergy and exports (29% of order book international). Gross margin improvement driven by higher international sales and engineering services expected to continue. H2FY24 anticipated to have stronger execution compared to H1, supporting revenue growth and margin expansion. EBITDA margins are expected to improve from current levels (~13%), driven by better execution and stable raw material costs. Capex of Rs. 120 crores for FY24 including Genx facility to support future manufacturing growth. Growth driver

IN US

Sale is live|00:00:00left today

Praj Industries LtdQ3 FY23Industrial Manufacturing

Praj Industries Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹342P/E: 101.6Market Cap: ₹7.5K CrSector: Industrial Manufacturing

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

- Expectation of continued growth in international sales, with export orders forming a larger share (29% in Q2 and 32% in H1 FY24 vs. 13% in H1 FY22). - Strong order inflow in bioenergy, engineering, and high purity segments indicates positive revenue momentum. - Increased traction in the US market with the first low carbon ethanol order received; more orders anticipated once US government clarifications on tax provisions are announced. - Growth in CBG segment driven by positive developments in ecosystem and strong interest from large corporates and OMCs. - Expansion in energy transition solutions including green hydrogen, green ammonia, and waste-to-energy projects via the Genx facility expected to contribute to growth. - Improvement in gross margins expected with favorable revenue composition (more exports and service orders). - Execution cycle expected to be H2 heavy, supporting revenue growth in the second half of FY24. Overall, management conveys a positive outlook for steady and sustainable growth in sales and volumes driven by diverse segments and international expansion.

Margin guidance

Category 2

→Positive business outlook with momentum building in international markets, especially in bioenergy and exports (29% of order book international).
→Gross margin improvement driven by higher international sales and engineering services expected to continue.
→H2FY24 anticipated to have stronger execution compared to H1, supporting revenue growth and margin expansion.
→EBITDA margins are expected to improve from current levels (~13%), driven by better execution and stable raw material costs.
→Capex of Rs. 120 crores for FY24 including Genx facility to support future manufacturing growth.
→Growth drivers include low carbon ethanol market in the US, energy transition (green hydrogen, ammonia), and bio-plastics pilot project commissioning.
→Strong order book of Rs. 39.6 billion with 74% domestic; exports gaining traction.
→Services segment small (~10-15 crores revenue) but growing.
→Overall, improving margins and expanding order pipeline support positive earnings and EPS growth trajectory over the near term.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript on page 18 and surrounding pages does not mention any current or planned fundraising through debt or equity.
→There is no discussion or indication of new capital raising activities.
→The focus is mainly on capital expenditure (CAPEX) plans (e.g., Rs. 100 crore for Genx facility, Rs. 40 crore for pilot plants), but funding sources for these are not explicitly stated as new debt or equity.
→Cash balance reported as Rs. 6.87 billion (Rs. 687 crore) as of Sept 30, 2023, which suggests internal resources may be used.
→No explicit mention of issuing new shares or taking on new loan facilities in the provided pages.

Order book

Yes

→Total order intake in the reported quarter was ₹10.63 billion, with 68% from bioenergy.
→CPES business's ETCA segment holds a significant 52% share in the overall order book.
→PHS business crossed ₹100 crore in order booking for the quarter.
→CBG segment has one confirmed order of around ₹100 crore; ₹400 crore worth orders are still at L1 stage as of 1st November.
→Five CBG projects awarded, with some delays due to land and registration issues, expected to progress once resolved.
→Healthy pipeline for 1G starch-based ethanol projects, with some temporary slowdown due to feedstock policies.
→Export orders now form approximately 29% of the current order book, with increasing traction internationally.
→Genx facility expected to start commercial production by Feb-Mar 2024, adding to future order execution.

Capex plans

Yes

→Praj Industries is setting up a new Genx manufacturing facility at Mangalore with commercial production expected by Feb-Mar FY24 end.
→Total CAPEX related to Genx is estimated at ₹100 crore, with ₹60 crore planned for the current year and ₹40 crore for the next year.
→Additional routine CAPEX for other facilities and IT is planned in the range of ₹15-20 crore.
→Two pilot plants are being set up for SAF (Sustainable Aviation Fuel) and PLA (Polylactic Acid) with a CAPEX of around ₹40 crore this year.
→Total CAPEX for the current year including Genx, routine expenses, and pilot plants is approximately ₹120 crore.
→A pilot project for bio-plastics technology demonstration is underway and expected to be commissioned in the last quarter of the financial year.

How does Praj Industries Ltd rank vs peers in Industrial Manufacturing?

Pro feature

1Praj Industries Ltd

Rev 3Mar 2

See full Industrial Manufacturing sector rankings

Want more stocks like Praj Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio